Effect of gifitinib combined with hydroxylcamptothecin pericardial perfusion in the treatment of advanced non-small cell lung cancer with pericardial effusion

Abstract

Objective To observe the clinical effect of gifitinib combined with hydroxylcamptothecin pericardial perfusion in the treatment of patients with advanced non-small cell lung cancer(NSCLC) with pericardial effusion. Methods From January 2016 to September 2017, eighty-four cases of late NSCLC with pericardial effusion treated in the People′s Hospital of Jiaozhou were randomly divided into two groups according to the digital table, with 42 cases in each group.The control group was treated with gefitinib, and the observation group was treated with hydroxylcamptothecin on the basis of the control group.The curative effect was evaluated after two courses of treatment in the two groups, and the clinical efficacy and adverse reactions were observed. Results The effective rates of the control group and the observation group were 47.6%(20/42) and 66.7%(28/42), respectively.The effective rate of the observation group was significantly higher than that of the control group(χ2=4.525, P<0.05). The effective rate of pericardial effusion was 33.3%(14/42) in the control group and 69.1%(29/42) in the observation group, the difference between the two groups was statistically significant(χ2=10.720, P<0.05). There was no ststistically significant difference in the incidence rate of adverse reactions between the two groups during treatment(P<0.05). Conclusion Combination of gefitinib and hydroxylcamptothecin pericardial perfusion in the treatment of NSCLC with pericardial effusion has good tolerance and good safety for the patients. Key words: Gefitinib; Hydroxycamptothecine; Drug therapy, combination; Chemotherapy, cancer, regional perfusion; Carcinoma, non-small-cell lung; Pericardial effusion; Treatment outcome; Controlled clinical trial